Genetics, pathogenesis and clinical interventions in type 1 diabetes
暂无分享,去创建一个
[1] C. Janeway,et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. , 2004, Diabetes.
[2] D. Bluemke,et al. Relation between carotid intima-media thickness and left ventricular mass in type 1 diabetes mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). , 2012, The American journal of cardiology.
[3] H. Mcdevitt,et al. Expansion of Functional Endogenous Antigen-Specific CD4+CD25+ Regulatory T Cells from Nonobese Diabetic Mice1 , 2005, The Journal of Immunology.
[4] R. Ley,et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes , 2008, Nature.
[5] A. Moore,et al. In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression , 2008, Magnetic resonance in medicine.
[6] Johnny Ludvigsson,et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. , 2008, The New England journal of medicine.
[7] J. Todd,et al. Rare Variants of IFIH1, a Gene Implicated in Antiviral Responses, Protect Against Type 1 Diabetes , 2009, Science.
[8] K. Yamagata,et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. , 1993, The Journal of clinical investigation.
[9] Christophe Benoist,et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters , 2009, Nature Medicine.
[10] Kara Hunter,et al. Type 1 diabetes genes and pathways shared by humans and NOD mice. , 2005, Journal of autoimmunity.
[11] M. Roncarolo,et al. Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.
[12] J. Petersen,et al. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. , 1999, Immunity.
[13] D. Vignali,et al. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. , 2009, Immunity.
[14] N. Morgan,et al. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes , 2009, Diabetologia.
[15] G. Karsenty,et al. CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET Results of a Multicentre Double-blind Trial , 1986, The Lancet.
[16] J. Voltarelli,et al. Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials , 2009, Diabetology & metabolic syndrome.
[17] A. Hämäläinen,et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study , 2005, Diabetologia.
[18] P. Hougaard,et al. Long-term risk of IDDM in first-degree relatives of patients with IDDM , 1994, Diabetologia.
[19] R. Tisch,et al. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. , 1998, Journal of immunology.
[20] J. Bluestone,et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.
[21] J. Todd,et al. HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk , 2008, Diabetes.
[22] S. Ziegler,et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. , 2006, The Journal of clinical investigation.
[23] Evon M. O. Abu-Taieh,et al. Comparative Study , 2020, Definitions.
[24] E. Sprecher,et al. Type 1 diabetes environmental factors and correspondence analysis of HLA class II genes in the Yemenite Jewish community in Israel. , 2001, Diabetes care.
[25] J. Buckner,et al. The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells1 , 2008, The Journal of Immunology.
[26] M. Peakman,et al. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group , 2010, Clinical and experimental immunology.
[27] Bhagirath Singh,et al. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. , 1997, Journal of autoimmunity.
[28] W. Hagopian,et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. , 2009, Clinical immunology.
[29] D. Zélénika,et al. CD4 T cells can reject major histocompatibility complex class I‐incompatible skin grafts , 1999, European journal of immunology.
[30] S. Richardson,et al. Analysis of islet inflammation in human type 1 diabetes , 2009, Clinical and experimental immunology.
[31] D. Serreze,et al. The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice , 2005, Immunological reviews.
[32] H. Jun,et al. A new look at viruses in type 1 diabetes. , 2003, Diabetes/metabolism research and reviews.
[33] T. Strom,et al. Cytokine related therapies for autoimmune disease. , 2008, Current opinion in immunology.
[34] B. Bisikirska,et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.
[35] Darrell M. Wilson,et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. , 2009, The New England journal of medicine.
[36] C. Benoist,et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors , 2008, Proceedings of the National Academy of Sciences.
[37] C. Benoist,et al. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes , 2009, Nature Immunology.
[38] R. Tisch,et al. On the Pathogenicity of Autoantigen-Specific T-Cell Receptors , 2008, Diabetes.
[39] S. Lieberman,et al. A comprehensive guide to antibody and T-cell responses in type 1 diabetes. , 2003, Tissue antigens.
[40] W. Suarez-Pinzon,et al. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. , 2005, Diabetes.
[41] Jeffrey A. Bluestone,et al. In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.
[42] H. Chase,et al. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. , 1999, Diabetes care.
[43] J. Krischer,et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. , 2005, Diabetes care.
[44] J. Killestein. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.
[45] J. Flier,et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts , 2007, Proceedings of the National Academy of Sciences.
[46] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[47] J. Bluestone,et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo , 2009, Nature Immunology.
[48] L. Wen,et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. , 2007, The Journal of clinical investigation.
[49] Jaakko Tuomilehto,et al. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study , 2008, The Lancet.
[50] J. Bluestone,et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.
[51] J. Kipnis,et al. Extracellular Redox Modulation by Regulatory T Cells† , 2009, Nature chemical biology.
[52] D. Bending,et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. , 2009, The Journal of clinical investigation.
[53] C. Benoist,et al. Physiological β Cell Death Triggers Priming of Self-reactive T Cells by Dendritic Cells in a Type-1 Diabetes Model , 2003, The Journal of experimental medicine.
[54] D. Greiner,et al. TLR9-Signaling Pathways Are Involved in Kilham Rat Virus-Induced Autoimmune Diabetes in the Biobreeding Diabetes-Resistant Rat1 , 2007, The Journal of Immunology.
[55] Y. Tochino,et al. Breeding of a non-obese, diabetic strain of mice. , 1980, Jikken dobutsu. Experimental animals.
[56] Camillo Ricordi,et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes , 1997, Nature Genetics.
[57] J. Bluestone,et al. Impairment of NK cell function by NKG2D modulation in NOD mice. , 2003, Immunity.
[58] G. Eisenbarth,et al. Interferon-α as a Mediator of Polyinosinic:Polycytidylic Acid–Induced Type 1 Diabetes , 2005 .
[59] Mark S. Anderson,et al. AIRE in the thymus and beyond. , 2009, Current opinion in immunology.
[60] Michel Goldman,et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.
[61] Jonathan H. Esensten,et al. T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function1 , 2009, The Journal of Immunology.
[62] M. Herrath. Faculty Opinions recommendation of Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. , 2003 .
[63] H. Waldmann,et al. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? , 1998, Annual review of immunology.
[64] J. Todd,et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus , 1997, Nature Genetics.
[65] M. Kenward,et al. Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes , 2006, Diabetologia.
[66] Mark S. Anderson,et al. The NOD mouse: a model of immune dysregulation. , 2005, Annual review of immunology.
[67] G. Eisenbarth,et al. Conserved T cell receptor α-chain induces insulin autoantibodies , 2008, Proceedings of the National Academy of Sciences.
[68] M. Ruth. Normalization of obesity-associated insulin resistance through immunotherapy , 2010 .
[69] C. Benoist,et al. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. , 2009, Immunity.
[70] C. Delcourt,et al. Analysis of mortality in French diabetic patients from death certificates: a comparative study. , 1999, Diabetes & metabolism.
[71] M. Rewers,et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. , 2007, JAMA.
[72] A. Laupacis,et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. , 1984, Science.
[73] D. Greiner,et al. The BB/Wor rat and the balance hypothesis of autoimmunity. , 1996, Diabetes/metabolism reviews.
[74] R. Tisch,et al. B Lymphocyte Depletion by CD20 Monoclonal Antibody Prevents Diabetes in Nonobese Diabetic Mice despite Isotype-Specific Differences in FcγR Effector Functions1 , 2008, The Journal of Immunology.
[75] U. Boggi,et al. Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients , 2007, Proceedings of the National Academy of Sciences.
[76] J. Krischer,et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. , 2006, Diabetes care.
[77] G. Eisenbarth,et al. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice , 2002, Nature Medicine.
[78] M. Mihatsch,et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. , 1988, The New England journal of medicine.
[79] M. Rewers,et al. Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done. , 2006, The Journal of clinical endocrinology and metabolism.
[80] D. Harlan,et al. A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.
[81] J. Bluestone,et al. CD3-specific antibodies: a portal to the treatment of autoimmunity , 2007, Nature Reviews Immunology.
[82] Bingye Han,et al. Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. , 2005, The Journal of clinical investigation.
[83] T. Tedder,et al. Regulatory B cells as inhibitors of immune responses and inflammation , 2008, Immunological reviews.
[84] P. Raskin,et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. , 2005, Diabetes care.
[85] M. Redondo,et al. Genetics of type 1A diabetes. , 2001, Recent progress in hormone research.
[86] D. Kioussis,et al. "Infectious" transplantation tolerance , 1993, Science.
[87] Qizhi Tang,et al. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.
[88] P. Halban,et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. , 2008, The Journal of clinical endocrinology and metabolism.
[89] M. Bhasin,et al. Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice , 2008, Proceedings of the National Academy of Sciences.
[90] G. Szot,et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice , 2008, Proceedings of the National Academy of Sciences.
[91] G. Eisenbarth,et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. , 1985, Diabetes research.
[92] S. Bonner-Weir,et al. Dimorphic histopathology of long-standing childhood-onset diabetes , 2010, Diabetologia.
[93] M. Dysken. A Review of Recent Clinical Trials in the Treatment of Alzheimer's Dementia , 1987 .